• Visionary Holdings posted first-half fiscal 2026 revenue of about US$434,648.
• Net loss attributable to shareholders narrowed to about US$2 million from about US$5.9 million a year earlier.
• Gross profit totaled about US$283,961, yielding a 65.3% gross margin.
• Total assets stood at about US$65.7 million at period end, with results still reflecting existing operations as biotech initiatives remain in development.
• Management said it is repositioning toward a biotechnology platform focused on stem cells and regenerative medicine, with AI and digital tools supporting research and precision-health applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visionary Holdings Inc published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.